Drugs / Allisartan Isoproxil/Amlodipine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06465264 | Apr 2021 → Aug 2022 | essential hypertension | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allisartan Isoproxil/Amlodipine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06465264 ↗ |
| Known as | ALI/AML | “This study aimed to assess the efficacy and safety of a combination therapy of Allisartan Isoproxil 240 mg and Amlodipine 5 mg (ALI/AML) compared to AML 5 mg monotherapy in...” PMID 39821945 ↗ Jan 2025 |